ArticleFrontiers in public health2025
Global, regional and national epidemiological trends of multiple myeloma from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Body mass index and multiple myeloma: a systematic review and dose-response meta-analysis of prospective cohort studies.BMC cancer · 2026Pooled it
- Incidence and Associated Risk Factors in the Development of Carfilzomib-Induced Cardiovascular Toxicity.Current oncology (Toronto, Ont.) · 2026Observational
- The Challenge of Determining the Etiology of Encephalopathy in an Elderly Patient.Clinical case reports · 2026Article
- Dorsal spinal instrumentation in multiple myeloma: postoperative acute kidney injury is associated with mortality, morbidity, and deterioration of bone and muscle status.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Article
- Psychosocial Functioning, Quality of Life, Depressive Symptoms, and Meaning in Life in Older Adults with Multiple Myeloma: A Cross-Sectional Study.International journal of environmental research and public health · 2026Article
- Predicting adverse events for risk stratification of chemotherapy based stem cell mobilization in multiple myeloma.NPJ digital medicine · 2026Article
- Burden of haematological malignancies among children, adolescents and young adults: Global and high-income region insights from the GBD 2021 study.British journal of haematology · 2026Article
- Single-cell RNA sequencing analysis revealed a potential association between ELK3 expression and the progression of multiple myeloma.Frontiers in immunology · 2026Article
- State of the Art of CAR-NK Cell Therapy in Multiple Myeloma: A Comprehensive Review of Cell Sources and Target Antigens.International journal of molecular sciences · 2025Review
- Unmasking Oligosecretory multiple myeloma: a case report highlighting diagnostic pitfalls.Oxford medical case reports · 2025Article
- The national and subnational burden of multiple myeloma (MM) in Italy from 1990 to 2023: results from the global burden of disease study 2023.EClinicalMedicine · 2025Article
- Global burden and trends of multiple myeloma attributable to high body mass index: a comprehensive analysis of the global burden of disease 2021 study with projections to 2040.BMC public health · 2025Article
- Global burden and trends of hematologic malignancies based on Global Cancer Observatory 2022 and Global Burden of Disease 2021.Experimental hematology & oncology · 2025Article
- Uncommon Entities, Uncommon Challenges: A Review of Rare Plasma Cell Disorders.Hematology reports · 2025Review
- Article
- Comparative analysis of stroke burden between ages 20-54 and over 55 years: based on the global burden of disease study 2019.BMC public health · 2025Article
- Identification and validation of a histone modification-related gene signature to predict the prognosis of multiple myeloma.Frontiers in genetics · 2025Article
- Burden of multiple myeloma in Asian countries from 1990 to 2021 and trend prediction for 2050: an analysis based on the Global Burden of Disease Study 2021.Frontiers in medicine · 2025Article
- Global, regional, and national metabolic risk factors associated with multiple myeloma, 1990-2021: analysis via the global burden of disease study 2021.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple myeloma (MM) is a growing global public health challenge. Known epidemiological data suggest that MM accounts for approximately 10% of all hematologic malignancies and remains the second most common hematologic cancer worldwide. This study utilized data from the 2021 Global Burden of Diseases (GBD) study to evaluate the prevalence, incidence, mortality, disability-adjusted life years (DALYs), and attributable risk factors of MM from 1990 to 2021, and to project future trends for the next 15 years. Methods: GBD 2021 data were analyzed to assess MM's global burden using four key epidemiological measures: prevalence, incidence, mortality, and DALYs. Estimates are reported per 100,000 population with uncertainty intervals (UI). Temporal trends were assessed through estimated annual percentage change (EAPC) and 95% confidence intervals (CI). All analyses were conducted using R version 4.2.1. Results: From 1990 to 2021, global MM prevalence, incidence, mortality, and DALYs more than doubled, particularly among males. All Social-Demographic Index (SDI) regions showed increases in ASPR, ASIR, ASMR, and ASDR (all EAPCs >0), with the middle SDI regions exhibiting the most rapid growth. ARIMA model predictions suggest that the MM burden will continue rising over the next 15 years. The proportion of MM cases attributable to high BMI also increased globally, from 6.40% in 1990 to 7.96% in 2021. MM primarily affects older adults, with the highest incidence observed in the 70-74 age group and the highest mortality rate recorded in the same age range. Conclusion: MM presents an escalating global health challenge. Targeted preventive interventions and improvements in diagnosis, treatment, and care are critical, especially in underdeveloped regions, to address the growing global burden of MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.